Rein Therapeutics (NASDAQ:RNTX) Releases Earnings Results, Beats Expectations By $0.30 EPS

Posted by Brenda Bartman on May 17th, 2026

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) announced its earnings results on Friday. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30, FiscalAI reports.

Rein Therapeutics Price Performance

NASDAQ:RNTX opened at $1.05 on Friday. Rein Therapeutics has a one year low of $1.00 and a one year high of $2.36. The company’s 50-day simple moving average is $1.37 and its 200 day simple moving average is $1.34. The firm has a market capitalization of $29.44 million, a P/E ratio of -0.55 and a beta of 1.42.

Institutional Investors Weigh In On Rein Therapeutics

Several hedge funds have recently bought and sold shares of RNTX. Geode Capital Management LLC bought a new stake in Rein Therapeutics during the second quarter worth about $344,000. Northwestern Mutual Wealth Management Co. bought a new stake in Rein Therapeutics during the second quarter worth about $68,000. Cable Car Capital LP bought a new stake in Rein Therapeutics during the second quarter worth about $588,000. Gagnon Securities LLC boosted its stake in Rein Therapeutics by 218.8% during the third quarter. Gagnon Securities LLC now owns 228,692 shares of the company’s stock worth $262,000 after acquiring an additional 156,947 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after acquiring an additional 284,300 shares in the last quarter. Institutional investors own 90.89% of the company’s stock.

Wall Street Analysts Forecast Growth

RNTX has been the topic of a number of research reports. lowered shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded Rein Therapeutics to a “sell” rating in a research report on Saturday. Finally, Citigroup lowered Rein Therapeutics to a “hold” rating in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

View Our Latest Stock Analysis on RNTX

Rein Therapeutics Company Profile

(Get Free Report)

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.